Understanding how psilocybin helps treat alcohol use disorder.
Neural mechanisms of psilocybin-assisted treatment for alcohol use disorder.
This study is looking at how psilocybin, a natural substance found in certain mushrooms, might help people who are trying to overcome alcohol addiction by changing their drinking habits and cravings, while also learning more about how it affects the brain.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10826792 on NIH RePORTER |
What this research studies
This research investigates the effects of psilocybin, a psychedelic compound, on individuals with alcohol use disorder (AUD). Through a double-blind randomized controlled trial, participants will receive psilocybin treatment to assess its impact on drinking behavior, cravings, and emotional responses. The study aims to explore the neural mechanisms involved in these changes using advanced imaging techniques. By understanding how psilocybin influences brain activity, the research seeks to improve treatment outcomes for those struggling with alcohol addiction.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with alcohol use disorder who are seeking treatment.
Not a fit: Patients who do not have alcohol use disorder or those who are not open to psychedelic treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel and effective treatment option for individuals with alcohol use disorder.
How similar studies have performed: Previous studies have shown promising results with psilocybin in treating various mental health conditions, indicating potential for success in this area as well.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Bogenschutz, Michael Parks — New York University School of Medicine
- Study coordinator: Bogenschutz, Michael Parks
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.